Literature DB >> 17922785

Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations.

Karl-Erik Andersson1, Brian Olshansky.   

Abstract

In this excellent mini-review, the authors present an extensive and relevant paper on the effect of antimuscarinic agents on the heart. This is without doubt the most detailed and the most reader-friendly paper on this subject, and I am sure that it will help urologists to assist in further educating their patients when prescribing these compounds.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17922785     DOI： 10.1111/j.1464-410X.2007.07100.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


  12 in total

1.  In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats.

Authors:  Takanobu Yamazaki; Yukiko Muraki; Tsuyoshi Anraku
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-08-05       Impact factor: 3.000

2.  Impact of Age and Polytherapy on Fingolimod Induced Bradycardia: a Preclinical Study.

Authors:  Christian Ritter; Martin K R Svačina; Ilja Bobylev; Abhijeet Joshi; Toni Schneider; Helmar C Lehmann
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-01       Impact factor: 4.147

3.  The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects.

Authors:  Maya Schiffers; Peter Sauermann; Brigitte Schurch; Ulrich Mehnert
Journal:  World J Urol       Date:  2010-02-07       Impact factor: 4.226

Review 4.  Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.

Authors:  Adrian S Wagg
Journal:  Drugs Aging       Date:  2012-07-01       Impact factor: 3.923

Review 5.  Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.

Authors:  Karin Glavind; Michael Chancellor
Journal:  Int Urogynecol J       Date:  2011-04-06       Impact factor: 2.894

Review 6.  Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.

Authors:  Karl-Erik Andersson; Lysanne Campeau; Brian Olshansky
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 7.  β3-receptor agonists for overactive bladder--new frontier or more of the same?

Authors:  Karl-Erik Andersson
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

8.  In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.

Authors:  C Salcedo; S Davalillo; J Cabellos; C Lagunas; D Balsa; S Pérez-Del-Pulgar; M Ballarín; Ag Fernández
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

Review 9.  What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?

Authors:  Romain Caremel; Oleg Loutochin; Jacques Corcos
Journal:  Int Urogynecol J       Date:  2013-08-07       Impact factor: 2.894

10.  New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.

Authors:  Karl-Erik Andersson
Journal:  Ther Clin Risk Manag       Date:  2013-04-18       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.